Mavacamten (Camzyos) is an oral cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
If you have a Hayes login, click here to view the full report on the Knowledge Center.